Celgene Corp. is a commercial-stage biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of small molecule drugs designed to treat cancer and immunological diseases through gene and protein regulation 

Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Pharmion's Oncology Portfolio Further Strengthens Celgene's Pipeline
Accelerates Celgene's Revenue and Earnings Growth, Accretive in 2009 and Beyond
SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--Nov. 18, 2007--Celgene Corporation (Nasdaq: CELG) and Pharmion Corporation (Nasdaq: PHRM) today jointly announced the signing of a definitive merger agreement pursuant to which Celgene has agreed to acquire Pharmion. Under the terms of the merger agreement, Celgene will acquire all of the outstanding shares of Pharmion common stock for $72.00 per share payable in a combination of cash and shares of Celgene common stock. The transaction is expected to be slightly dilutive to earnings in 2008 and accretive in 2009 and beyond.
The acquisition of Pharmion furthers Celgene's strategy to become a global leader in the hematology/oncology field. The transaction brings together three medically meaningful therapies, Revlimid(R), Thalomid(R) and Vidaza(R), treating different patient populations worldwide. These products are expected to generate multiple global revenue streams for accelerated revenue and earnings growth over the next five years

Celgene Corporation to Announce Second Quarter Results on July 26, 2007
SUMMIT, N.J.--(BUSINESS WIRE)--July 10, 2007--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 26, 2007 at 9:00 am EDT to discuss the Company's second quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com

Celgene Corporation Reports Record Third Quarter Revenue and Operating Profits 
  Product Sales Drive Record Third Quarter Revenue and Profits:
    * Record Net Product Sales of $223.1 Million
        - REVLIMID Achieved $101.3 Million in Net Product Sales
        - THALOMID Net Product Sales Totaled $108.4 Million
    * Record Adjusted Net Income of $59.4 Million with Adjusted Diluted Earnings Per Share of $0.15
    Financial Highlights of Third Quarter Performance Year-Over-Year:
    * Total Revenue Increased 89.1% to a Record $244.8 Million
    * Adjusted Operating Income Increased 682.1% to $79.4 Million
    * Adjusted R&D Expenditures Increased to $64.1 Million to Support  Continued Expansion of Both REVLIMID and Promising Pipeline Clinical   Programs
    * Adjusted SG&A Expenses Increased to $67.3 Million to Support Commercial  Activities for Multiple Product Launches, Including Preparations for   International Launches

SUMMIT, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced adjusted net income of $59.4 million, or adjusted earnings per diluted share of $0.15 for the quarter ended September 30, 2006. Based on U.S. Generally Accepted Accounting Principles (GAAP), Celgene reported net income of $20.4 million, or diluted earnings per share of $0.05 for the quarter ended September 30, 2006, including share-based employee compensation expense, compared to net income in the prior year period of $0.7 million. Total revenue was a record $244.8 million for the quarter ended September 30, 2006, an increase of 89.1% over the same period in 2005 driven by REVLIMID net sales of $101.3 million, and THALOMID net sales of $108.4 million, an increase of 9.3% year-over-year. ALKERAN(R) net sales for the Third Quarter were $12.2 million in 2006 compared to $13.9 million in 2005. Revenue from Focalin(TM) and the Ritalin(R) family of drugs totaled $17.9 million for the Third Quarter of 2006 compared to $10.7 million over the same period last year.

For the nine-month period, total net product sales reached a record $559.7 million, an increase of 76.6% over the same period in 2005. REVLIMID(R) sales for the nine-month period reached $196.8 million. THALOMID(R) sales for the nine-month period of 2006 were $322.8 million compared to $282.0 million in 2005, an increase of 14.5% year-over-year. Celgene posted adjusted net income of $135.7 million or adjusted earnings per diluted share of $0.35, during the nine-month period of 2006, compared to adjusted net income of $60.6 million or adjusted earnings per diluted share of $0.17 in the comparable 2005 period. During the nine-month period on a reported basis of 2006, Celgene announced GAAP net income of $46.1 million or earnings per diluted share of $0.12, compared to GAAP net income of $59.7 million or earnings of $0.16 per diluted share in the first nine-months of last year, which did not include charges for stock option expense.

Adjusted net income and adjusted per share amounts for the three and nine- month periods ended September 30, 2006, eliminate the effects of charges for share-based employee compensation expense associated with the application of the Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), "Share-Based Payment", (SFAS 123(R)). The after tax net impact of share-based employee compensation expense reduced GAAP net income by $15.4 million, or $0.04 per diluted share for the three-month period ended September 30, 2006 and by $40.6 million, or $0.10 per diluted share for the nine-month period ended September 30, 2006. Adjusted net income and per share amounts, for the three-month and nine-month periods ended September 30, 2006 and 2005, excludes amortization of acquisition intangibles resulting from the acquisition of Penn T Limited and charges to record our share of equity losses in EntreMed, Inc. Also, adjusted net income and per share amounts, for the three-month period ended September 30, 2006 and nine-month periods ended September 30, 2006 and 2005 excludes gains (losses) recorded for changes in the estimated value of our investment in EntreMed, Inc. warrants. The nine-month periods ended September 30, 2006 and 2005, and the three-month period ended September 30, 2005, also excludes accelerated depreciation expense related to the Company's corporate headquarters relocation. Adjusted net income and per share amounts, for the nine-month period ended September 30, 2006 and 2005 includes adjustments to the income tax provision to reflect a projected cash tax rate of 32.0% and 28.0%, respectively.